Stem cells, exosomes and PRP: what regenerative medicine is (and isn't)

What regenerative medicine is

Regenerative medicine describes treatments designed to support the body's own repair processes rather than simply manage symptoms. In practice the term covers several distinct approaches: platelet-rich plasma (PRP) made from your own blood, and cell-based options such as stem cells, exosomes, and secretome products. The evidence, the regulation, and the risks are different for each, so lumping them together under one label is the first mistake to avoid.

PRP: the most established option

PRP concentrates the platelets from a sample of your own blood and injects them into an area of injury, most often a tendon or a joint. Because it uses your own blood and is minimally manipulated, PRP sits in a different regulatory category than cell-based products. The evidence is strongest for certain tendon problems and knee osteoarthritis: a 2017 meta-analysis of randomized trials found PRP more effective than control injections for symptomatic tendinopathy, and a 2023 meta-analysis found PRP improved pain and function in knee osteoarthritis. Even here, results vary by condition and formulation, and PRP is not supported for every use.

Stem cells, exosomes, and secretomes: the regulatory reality

Cell-based products are a different story. The FDA's consumer alert on regenerative medicine products is worth reading in full. The only FDA-approved stem cell products in the United States are blood-forming stem cells for certain blood and immune disorders; no stem cell product is approved for joint pain, arthritis, or anti-aging. There are currently no FDA-approved exosome products, and the FDA has stated that exosome and secretome products intended to treat disease are regulated as drugs and biologics that require premarket approval. The FDA has issued safety notifications about unapproved exosome products after serious adverse events. Translation: any clinic presenting exosomes, secretomes, or stem cells as a routine, FDA-approved treatment for pain or aging is overstating what is established.

How to evaluate a regenerative medicine offer

A responsible practice behaves like a medical office, not a salesroom. Expect a real evaluation to confirm whether you are a candidate at all, a plain-language discussion of what is and is not proven for your condition, clarity about what is FDA-approved versus emerging, and an honest explanation of risks and limitations. Any offer that promises guaranteed results, uses the words "cure" or "reverse," or pressures you to book is a red flag.

Where APRM Solutions fits

APRM Solutions organizes its verified regenerative offerings, including PRP-related services and its cell-based options, into clearly described programs that are evaluated per patient. The team explains the evidence honestly, separates established options from emerging ones, and reviews regulatory considerations before any treatment is discussed. If regenerative medicine is something you are considering, start with the evaluation and the honest conversation.